By Fineline Cube 
China-based Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) announced the signing of a strategic cooperation agreement in Suzhou. The partnership will focus on supplying peptide raw materials for BrightGene’s innovative drugs in overseas commercialization, marking a significant step in supporting BrightGene’s global industrialization efforts.
Collaboration Details
Under the agreement, Hybio Pharmaceutical will utilize its strengths in international registration and large-scale production to ensure a stable supply of raw materials for BrightGene’s metabolic pipeline, particularly its oral peptide products. This long-term cooperation aims to support BrightGene’s global industrialization process for its innovative drugs.
BrightGene’s Perspective
BrightGene’s Chairman, Yuan Jiandong, highlighted that Hybio’s peptide API base has a production capacity exceeding one ton and complies with EU and U.S. GMP standards. This capability positions Hybio as a reliable partner to meet the overseas market demands for BrightGene’s drugs.
Hybio’s Capabilities and BrightGene’s Global Presence
Hybio Pharmaceutical, a national high-tech enterprise specializing in peptide and oligonucleotide drugs, offers integrated capabilities for international expansion from raw materials to finished products. BrightGene, focusing on R&D for innovative drugs in the metabolic and respiratory fields, has established a global production system covering China, the U.S., Europe, Japan, and South Korea. This strategic partnership leverages the strengths of both companies to advance the commercialization of innovative therapies on a global scale.-Fineline Info & Tech